Cognition and depression: the effects of fluvoxamine, a sigma‐1 receptor agonist, reconsidered

  title={Cognition and depression: the effects of fluvoxamine, a sigma‐1 receptor agonist, reconsidered},
  author={Ian Hindmarch and Kenji Hashimoto},
  journal={Human Psychopharmacology: Clinical and Experimental},
Cognitive impairment is a primary feature of patients with major depressive disorder (MDD) and is characterised by stress‐induced neural atrophy. Via alpha‐adrenergic, anti‐cholinergic and anti‐histaminic activities, several antidepressants can cause significant counter‐therapeutic cognitive impairment. Evidence is emerging of the involvement of sigma‐1 receptor agonism in the mechanism of action of some antidepressants, notably fluvoxamine. Sigma‐1 receptors are abundant in areas affected by… 
The role of glutamate on the action of antidepressants
  • K. Hashimoto
  • Biology, Psychology
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2011
Psychopharmacology of combined activation of the serotonin1A and &sgr;1 receptors
Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders.
The role of s Sigma-1 receptors in the mechanistic action of some SSRIs, donepezil, neurosteroids, and ifenprodil, and the clinical implications for sigma-1 receptor agonists are discussed.
The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report
Doctors should consider the monotherapy of sigma-1 receptor agonist fluvoxamine as an alternative approach to treating psychotic major depression.
Neuropharmacologic studies on the brain serotonin1A receptor using the selective agonist osemozotan.
  • T. Matsuda
  • Biology, Psychology
    Biological & pharmaceutical bulletin
  • 2013
It is shown that osemozotan attenuates psychostimulant-induced behavioral sensitization and that prefrontal dopamine release is enhanced by functional interaction between the 5-HT1A receptor and other receptors, and suggests that the5-HT 1A receptor may be a target molecule for the treatment of psychiatric disorders, pain, and drug dependence.
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Substances regulating activation/inhibition of the NMDA receptor have been investigated in schizophrenia and major depression and are promising in therapeutic approaches of negative symptoms, cognition, and mood and should be investigated to elucidate neural mechanisms underlying efficacy.
Dextromethorphan as a potential rapid-acting antidepressant.
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
A lack of understanding of the complexities and interactions between SSRIs in the developing brain of a young person with depression means that adults, who do not have certain risk factors, do not seem to carry this increased risk of suicidality.
An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies
The evidence for sigma-1 activity in reducing seizure frequency and promoting neuroprotection in the context of DEE pathophysiology and clinical presentation is reviewed, using fenfluramine as a case example.
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
This work aims to be a reference for psychiatrists who may soon be faced with the possibility of prescribing psychedelic compounds as medications, helping them assess which compound(s) and regimen could be most useful for decreasing specific psychiatric symptoms.


Sigma‐1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance
  • F. Monnet
  • Biology, Psychology
    Biology of the cell
  • 2005
Recent data is presented supporting the notion that drugs acting via the endoplasmic reticulum‐coupled sigma‐1 receptor might reverse these deleterious events by restoring both extra‐ and intra‐cellular Ca2+‐dependent neuronal responses.
Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia
Antidepressant Treatment of Psychotic Major Depression: Potential Role of the σ Receptor
It is proposed that the apparent efficacy of fluvoxamine in psychotic major depression may be related to its unique property of high affinity for the σ1receptor, which is thought to play a role in psychosis and in the action of some antipsychotic drugs.
The role of the hippocampus in the pathophysiology of major depression.
Data from imaging studies suggest both structural changes in the volume of the HC and functional alterations in frontotemporal and limbic circuits that may be critical for mood regulation in patients with MDD.
Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands
Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients
Evidence is added that antidepressant drugs with high anticholinergic activity can impair memory, despite alleviation of depression, by testing the alternative hypothesis that amitriptyline would exacerbate depressed patients' cognitive disturbances.
Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors
The impairing and facilitating cognitive effects of paroxetine and sertraline, respectively, may be more pronounced in the elderly depressed patient and can be explained by subtle differences in pharmacological profiles of these SSRIs.
Neurocognitive impairment in drug-free patients with major depressive disorder
Pronounced neurocognitive impairment was found in this sample of young adult out-patients with MDD, and could therefore provide an objective marker of brain dysfunction in depression.
Strain differences in σ1 receptor‐mediated behaviours are related to neurosteroid levels
It is suggested that strain differences in neuroactive steroid and particularly, progesterone, biosynthesis and sensitivity may contribute to the differential behavioural efficacy of σ1‐receptor ligands.